Tenofovir disoproxil orotate

Drug Profile

Tenofovir disoproxil orotate

Alternative Names: DA 2802

Latest Information Update: 27 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dong-A ST
  • Class Antiretrovirals; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 16 Nov 2016 Dong-A ST plans a phase III trial for chronic Hepatitis B in South Korea (PO, Tablet) (NCT02967939)
  • 08 Mar 2016 Dong-A ST completes a phase I trial in Hepatitis B (In adults, In volunteers) in South Korea (PO) (NCT02557594)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top